Intervention Protocol

You have free access to this content

Oxandrolone for growth-hormone treated children and adolescents with Turner syndrome

  1. Sarar Mohamed1,*,
  2. Yaser Adi2,
  3. Khalid AlFaleh3

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 9 SEP 2013

DOI: 10.1002/14651858.CD010736


How to Cite

Mohamed S, Adi Y, AlFaleh K. Oxandrolone for growth-hormone treated children and adolescents with Turner syndrome (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD010736. DOI: 10.1002/14651858.CD010736.

Author Information

  1. 1

    King Khalid University Hospital and College of Medicine, Department of Paediatrics, Riyadh, Saudi Arabia

  2. 2

    College of Medicine /King Saud University, Shaikh Abdullah Bahamdan's Research Chair for Evidence-Based Health Care and Knowledge Translation, Riyadh, Saudi Arabia

  3. 3

    King Saud University, Department of Pediatrics (Division of Neonatology), Riyadh, Saudi Arabia

*Sarar Mohamed, Department of Paediatrics, King Khalid University Hospital and College of Medicine, King Saud University, PO Box 2925, Riyadh, 11461, Saudi Arabia. msarar@ksu.edu.sa. sararmohamed@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 9 SEP 2013

SEARCH

 

Background

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Turner syndrome (TS) is one of the common chromosomal abnormalities in girls. TS was initially described by Otto Ullrich in 1930 and later in 1938 by Henry Turner who described this syndrome in seven females with short stature, sexual infantilism, webbed neck and cubitus valgus (Turner 1938; Ullrich 1930). The incidence of TS is 1 in 2000 to 2500 female live births (Nielsen 1991; Pinsker 2012; Stochholm 2006). Most of the pregnancies with TS result in abortion. Gravholt et al studied the prevalence of TS karyotypes among prenatally tested fetuses and TS among liveborn infants in Denmark from 1970 to 1993 (Gravholt 1996). Their data showed that among female fetuses tested by amniocentesis, the prevalence of TS karyotypes was 176/100,000 while the prevalence was 392/100,000 among female fetuses tested by chorion villus sampling. These data proved that the prevalence of TS is not only influenced by testing during pregnancy or after birth but also depends on the method of prenatal testing (Gravholt 1996).

 

Description of the condition

TS is characterised by complete or partial loss of the second X chromosome (Nielsen 1991). Complete loss of one X chromosome (45 X) results in classical features of the disease while mosaics present with varying and generally lesser degrees of manifestation. Variable aberrations of the second X chromosome such as deletion, ring chromosome, and isochromosome cause phenotypic features of TS in 46 XX patients. The most frequent chromosomal abnormality in TS is 45 X (Nielsen 1991; Pinsker 2012; Stochholm 2006). The Danish TS registry showed that the 45 X karyotype was found in half of patients, followed by mosaics (Gravholt 1996).

TS is a multisystem disorder with the cardiovascular, skeletal, endocrine and reproductive systems mostly affected (Stochholm 2006). Lymphoedema of the hand and foot is an early sign of TS. Other dysmorphic features include widely spaced nipples, cubitus valgus, short webbed neck, low posterior hairline and narrow hyperconvex nails (Baxter 2007; Nielsen 1991; Pinsker 2012; Stochholm 2006). Congenital heart diseases are more frequent in individuals with TS compared to the general population (Stochholm 2006). The Italian study group for TS reported on cardiac anomalies in 594 patients with the disease (Mazzanti 1998). The prevalence of cardiac malformations in this study was 23%, with bicuspid aortic valve (12.5%), aortic coarctation (6.9%) and aortic valve disease (3.2%). Growth failure in childhood leading to short final adult height is the cardinal sign in girls with TS (Pinsker 2012; Stochholm 2006). While their birth weight is slightly impaired in utero, girls with TS may present early in childhood with failure to thrive (Davenport 1999). The height of patients with TS, when plotted on growth curves specific for this disorder, shows that growth velocity declinesbelow the reference growth curve for females often as early as two to four years of age (Saenger 1999). The adult height (defined as the height at which the epiphyses are closed or height velocity is less than 1 cm/year) of Turner patients is approximately 20 cm below that of the average female population. Naeraa and Nielsen studied growth parameters in 78 patients with TS (Naeraa 1990; Nielsen 1991). Analysis of the growth pattern showed that though no pubertal growth spurt was present, the steady decrease of height velocity (defined as increment in height per year in centimetres) was interrupted at the age of nine years. Height velocity was then constant until 12 years of age, thereafter it slowly decreased. The mean final height of this cohort was 146.8 cm (SD 5.8 cm, N = 76) compared to 166.8 cm in the general female population (Naeraa 1990). Therefore, short final adult height in TS is explained by poor childhood growth in addition to the lack of a pubertal growth spurt.

Hypergonadotrophic hypogonadism resulting from ovarian failure is a cardinal feature of TS. Primary infertility and lack of pubertal signs are seen in the vast majority of girls with TS (Bondy 2007). Spontaneous puberty and rarely pregnancy are reported in a minority of patients with TS, most of them carrying mosaic karyotype (Tracy 2011). Assisted reproduction remains an option to achieve pregnancy for women with primary ovarian failure including those with TS (Tracy 2011).

Characteristic neurocognitive features of TS include normal verbal function and impaired visual-spatial and perceptual abilities, attention, working memory, and spatially dependent executive function (Ross 2006). However, global developmental delay is uncommon in TS (Nielsen 1991; Pinsker 2012; Stochholm 2006). Short stature, delayed puberty and the presence of dysmorphic features contribute to the social and emotional impairment observed in TS (Ross 2006). Failure to treat growth and puberty stigmata may lead to further psychological and psychiatric problems (Bondy 2007; Carel 2006).

 

Description of the intervention

 

Growth hormone

Growth hormone (GH) is a peptide hormone secreted by the anterior pituitary gland. GH promotes linear growth by stimulating production of insulin-like growth factor 1 that acts at the growth plate by enhancing differentiation of prechondrocytes and the expansion of osteoblasts (Reh CS 2010).

GH is currently used as a once-daily subcutaneous injection, typically given late in the evening to mimic the physiological secretory pattern of endogenous GH (Reh CS 2010). There is a wide range of recommended dosing of GH internationally for the treatment of growth-hormone deficiency. The dose of GH ranges between 0.5 to 0.7 IU/kg/week (0.17 to 0.23 mg/kg/week) in most countries (Tanaka 1999).

GH is generally safe with adverse events such as benign intracranial hypertension, slipped femoral epiphysis, worsening of scoliosis and impaired glucose homeostasis infrequently observed (Bell 2010; Wilton 1999).

Recombinant human GH was approved by the US Food and Drug Administration (FDA) for use in children with GH deficiency in 1985 and for TS in 1996. In the last three decades, multiple studies have confirmed the effectiveness and safety of GH therapy (Bell 2010; Reh CS 2010; Tanaka 1999; Takeda 2010).

Currently GH therapy is recommended for all children and adolescents with TS as the evidence supports this intervention (Baxter 2007; Canadian Growth Hormone Advisory Committee 2005; Takeda 2010). Standard management of TS entails starting GH in childhood to maximise height gain and to improve the final adult height (Bondy 2007; Davenport 2007; Ranke 2007; Stephure 2005). Furthermore, treatment with GH positively affects body composition by increasing muscle mass and decreasing fat mass (Gravholt 2002). A Cochrane systematic review investigated the effects of GH in children and adolescents with TS (Baxter 2007). Four randomised controlled trials (RCTs) that included 365 participants after one year of treatment were included. This systematic review concluded that GH increases short-term growth in girls with TS by approximately 3 cm in the first year of treatment and 2 cm in the second year. In one trial treatment increased final height by approximately 6 cm over the height in an untreated control group. The optimal age for initiation of GH therapy for young children has not been established. Davenport et al showed that early GH treatment can correct growth failure and normalize height in infants and toddlers with TS (Fechner 2007).

Carel et al carried out a population-based cohort study of health-related quality of life determinants in 568 young women with TS using the 'Medical Outcome Study Short Form 36' (SF-36) score and the 'General Health Questionnaire' 12 score (Carel 2005; Carel 2006). This study concluded that health-related quality of life is normal and unaffected by height in young adults with TS treated with GH. Similar results were reported by Taback et al who conducted a follow-up study on the health-related quality of life of young adults from a long-term controlled trial of GH treatment in patients with TS (Taback 2011). This study found no benefit or adverse effects on health-related quality of life either from receiving or not receiving GH injections in a long-term RCT.

The majority of patients with TS have delayed puberty leading to the lack of a pubertal growth spurt, which compromises the final adult height. Therefore oestrogen is commonly started on top of GH in order to induce puberty and maximize final adult height (Bondy 2007; Van Pareren 2003).

The age of starting oestrogen in patients with TS as well as the dose and the duration of therapy varies considerably among physicians (Bondy 2007; Pinsker 2012; Van Pareren 2003).

 

Oxandrolone

Oxandrolone (Ox) is an anabolic steroid (a synthetic derivative of testosterone). It is a weak androgen (Menke 2011) and is available in 2.5 mg and 10 mg tablets. The dose for children is weight based (0.1 mg/kg), however have been wide variations in the Ox dose (mostly 0.03 to 0.06 mg/kg/d) used in different studies investigating growth promotion in TS (Bareille 1997; Gault 2011; Job 1991; Joss 1984; Menke 2010Nilsson 1996; Rosenfeld 1992Stahnke 2002; Zeger 2011). Recently a stable and validated liquid formulation of oxandrolone has been developed. This formulation uses commercially available oxandrolone tablets which are crushed and dispersed in syrup (Garg 2011). Historically, Ox was initially approved in 1964 for treatment of wasting associated with conditions such as chronic infection, severe trauma, and after extensive surgery (Mann 1999). In the last two decades, Ox was used as an adjuvant therapy to promote healing in severe burning (Hart 2001; Sheffield-Moore 1999).

In order to improve growth, Ox is usually started a few years before the appropriate age for induction of puberty in girls with TS. Both GH and Ox are discontinued when the adult final height has been achieved (Bondy 2007; Stochholm 2006).

 

Adverse effects of the intervention

Adverse effects associated with Ox include signs of virilization such as clitoral enlargement, acne, lowering of the voice, and more rapid skeletal maturation (Carolyn 2007).

 

How the intervention might work

Although Ox is a known anabolic steroid, the exact mechanism by which Ox improves growth is unknown. It may act directly on the growth plate (Haeusler 1996; Sheffield-Moore 1999; Wilson 1998). The advantage of Ox over other growth promoting androgens is that it may improve the final adult height and at the same time does not promote bone maturation that leads to early fusion of the epiphysis (Bareille 1997; Gault 2011; Haeusler 1996; Job 1991; Joss 1984; Menke 2010Nilsson 1996; Rosenfeld 1992Stahnke 2002; Wilson 1998; Zeger 2011).

 

Why it is important to do this review

The use of Ox as an adjuvant therapy to GH aiming to maximize the final adult height is unclear. There is currently no published systematic review investigating the role of Ox in the management of girls with TS. Therefore, we would like to conduct a systematic review to evaluate the effects and safety of Ox in patients with TS already treated with GH. This will help physicians and health policy developers to make evidence-based recommendations regarding the role of Ox in TS.

 

Objectives

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

To assess the effects of oxandrolone on growth-hormone treated children and adolescents with Turner syndrome (TS).

 

Methods

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support
 

Criteria for considering studies for this review

 

Types of studies

Randomised controlled clinical trials (RCTs).

 

Types of participants

Growth-hormone treated children and adolescents with TS.

 

Diagnostic criteria

As some patients with TS lack the clinical phenotype suggestive of the disease, all participants included in this review should have their diagnosis of TS confirmed by a chromosomal study. This includes complete (45 X) or partial loss of the second X chromosome (such as deletion, ring chromosome, and isochromosome). Mosaics will also be included in this review.

 

Types of interventions

Growth hormone (GH) treatment should have been given for at least one year. All other concurrent therapies should be comparable between the intervention and comparator groups.

 

Intervention

  • Oxandrolone and GH treatment.

 

Comparator

  • GH treatment only.

 

Types of outcome measures

 

Primary outcomes

  • Improvement in final adult height or increase in height velocity in children who had not reached their final adult height
  • Health-related quality of life
  • Adverse effects (e.g. virilization effects on hair distribution, deepening of voice, clitromegaly)

 

Secondary outcomes

  • All-cause mortality
  • Bone maturation
  • Effects on cognition
  • Effects on psychological status
  • Effects on speech
  • Socioeconomic costs

 
Timing of outcome measurement

Short-term outcome measurements include measurement of annual height velocity and observing adverse effects in the first year of intervention. Medium-term outcomes include attaining near adult height (defined as age at which the height velocity is 2 cm per year). Long-term outcome measurements include measuring final adult height when epiphyses are closed and assessing the effects of the intervention on health-related quality of life.

 
Definition of outcome measurement

  • Bone maturation has to be assessed by X-ray of the left hand for bone age and closure of the epiphysis.
  • Effects on cognition have to be measured by a validated instrument like the 'Wechsler Intelligence Scale for Children Third Edition' (Wechsler 1991).
  • Effects on psychological status have to be measured by a validated instrument such as the 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-4) (Conway 2012).
  • Effects on speech have to be assessed by the speaking fundamental frequency (Andersson-Wallgren 2008).
  • Final adult height is defined as the height at which epiphyses are closed or height velocity is less than 1 cm per year (Bondy 2007; Stochholm 2006).
  • Health-related quality of life has to be measured by a validated instrument like the 'SF-36' (Carel 2005; Carel 2006).
  • Height velocity is defined as increment in height per year in centimeters.

 
Summary of findings table

We will present a 'Summary of findings' table reporting the following outcomes listed according to priority.

  1. Final adult height.
  2. Adverse events.
  3. Health-related quality of life.
  4. Effects on speech.
  5. Effects on cognition.
  6. Effects on psychological status.
  7. All-cause mortality.

 

Search methods for identification of studies

A comprehensive search will be conducted using primarily electronic databases. The following words will be used: Turner's Syndrome AND oxandrolone using a combination of both MeSH terms (medical subheadings) and text words.

 

Electronic searches

We will search the following sources from inception to the present.

  • The Cochrane Library.
  • MEDLINE.
  • EMBASE.

We will also search databases of ongoing trials including ClinicalTrials.gov (http://clinicaltrials.gov/), metaRegister of Controlled Trials (http://www.controlled-trials.com/mrct/), the EU Clinical Trials register (https://www.clinicaltrialsregister.eu/) and the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal (http://apps.who.int/trialsearch/).

For detailed search strategies please see Appendix 1. We will continuously apply PubMed's 'My NCBI' (National Center for Biotechnology Information) e-mail alert service for identification of newly published studies using a basic search strategy (see Appendix 1). Four weeks before we submit the final review draft to the Cochrane Metabolic and Endocrine Disorders Group (CMED) for editorial approval we will perform a complete updated search on all specified databases. Should we detect new studies for inclusion we will evaluate these and incorporate findings in our review before submission of the final review draft.

If we detect additional relevant key words during any of the electronic or other searches, we will modify the electronic search strategies to incorporate these terms and document the changes. We will place no restrictions on the language of publication when searching the electronic databases or reviewing reference lists in identified studies.

We will send results of electronic searches to the CMED for databases which are not available at the editorial office.

 

Searching other resources

We will try to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, (systematic) reviews, meta-analyses, and health technology assessment reports.

Oxadrolone manufacturers' websites, FDA and European Medicines Agency (EMA) websites will be searched.

 

Data collection and analysis

 

Selection of studies

To determine the studies to be assessed further, three review authors (SM, YA, KA) will independently scan the abstract, title, or both sections of every record retrieved. We will investigate all potentially relevant articles as full texts. Where differences in opinion exist, they will be resolved by a third party (editorial office). If resolving the disagreement is not possible, the article will be added to those 'awaiting assessment' and we will contact the study authors for clarification. We will attach an adapted PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow-chart of study selection (Figure 1) (Liberati 2009).

 FigureFigure 1. Study flow diagram.

 

Data extraction and management

For studies that fulfil the inclusion criteria, three review authors (SM, YA, KA) will independently abstract relevant population and intervention characteristics using a standard data extraction template (for details see  Table 1; Appendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8; Appendix 9; Appendix 10; Appendix 11) with any disagreements to be resolved by discussion or, if required, by a third party (editorial office).

We will provide information, including trial identifier, about potentially-relevant ongoing studies in the table 'Characteristics of ongoing studies' and in the appendix 'Matrix of study endpoints (trial documents)'. We will try to find the protocol of each included study, either in databases of ongoing trials, or in publications of study designs, or both, and specify the data in the appendix 'Matrix of study endpoints (trial documents)'.

We will send an e-mail to all study authors of included studies to enquire whether they are willing to answer questions regarding their trials.The results of this survey will be published in Appendix 12. Thereafter, we will seek relevant missing information on the trial from the primary author(s) of the article, if required.

 

Dealing with duplicate publications and companion papers

In the event of duplicate publications, companion papers, or multiple reports of a primary study, we will maximize the yield of information by collating all available data. In case of doubt, the publication reporting the longest follow-up associated with our primary or secondary outcomes will obtain priority.

 

Assessment of risk of bias in included studies

Three review authors (SM, YA, KA) will assess each trial independently. We will resolve possible disagreements by consensus, or in consultation with a third party. In cases of disagreement, the editorial office will be consulted and a judgement will be made based on consensus.

We will assess risk of bias using The Cochrane Collaboration’s tool (Higgins 2011; Higgins 2011a). We will use the following bias criteria.

  • Random sequence generation (selection bias).
  • Allocation concealment (selection bias).
  • Blinding (performance bias and detection bias), separated for blinding of participants and personnel and blinding of outcome assessment.
  • Incomplete outcome data (attrition bias).
  • Selective reporting (reporting bias).
  • Other bias.

We will assess outcome reporting bias by integrating the results of 'Examination of outcome reporting bias' (Appendix 7), 'Matrix of study endpoints (trial documents)' (Appendix 6) and section 'Outcomes (outcomes reported in abstract of publication)' of the 'Characteristics of included studies' section (Kirkham 2010). This analysis will form the basis for the judgement of selective reporting (reporting bias).

We will judge risk of bias criteria as 'low risk', 'high risk' or 'unclear risk' and evaluate individual bias items as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will attach a 'risk of bias' graph and 'Risk of bias summary' figure.

We will assess the impact of individual bias domains on study results at the endpoint and study levels.

For blinding of participants and personnel (performance bias), detection bias (blinding of outcome assessors), and attrition bias (incomplete outcome data) we intend to evaluate risk of bias separately for subjective and objective outcomes (Hróbjartsson 2013). We will consider the implications of missing outcome data from individual participants.

We define the following outcomes as subjective outcomes.

  • Health-related quality of life.
  • Effects on speech.
  • Effects on cognition.
  • Effect on psychological status.
  • Adverse events.

We define the following outcomes as objective outcomes.

  • Increment in height velocity and final adult height.
  • Bone maturation.
  • All-cause mortality.
  • Socioeconomic costs.

 

Measures of treatment effect

We will express dichotomous data as odds ratios (ORs) or risk ratios (RRs) with 95% confidence intervals (CIs). We will express continuous data as differences in means (MD) with 95% CI.

 

Unit of analysis issues

We will take into account the level at which randomisation occurred, such as cluster-randomised trials and multiple observations for the same outcome.

 

Dealing with missing data

We will obtain relevant missing data from authors, if feasible, and carefully perform evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and per protocol (PP) populations. We will investigate attrition rates, for example dropouts, losses to follow-up, and withdrawals and critically appraise issues of missing data and imputation methods (for example last observation carried forward (LOCF)).

 

Assessment of heterogeneity

In the event of substantial clinical, methodological or statistical heterogeneity, we will not report study results as the pooled effect estimate in a meta-analysis. We will identify heterogeneity by visual inspection of the forest plots and by using a standard Chi2 test with a significance level of α = 0.1, in view of the low power of this test. We specifically will examine heterogeneity employing the I2 statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (Higgins 2002; Higgins 2003), where an I2 statistic of 75% and more indicates a considerable level of inconsistency (Higgins 2011).

When we find heterogeneity, we will attempt to determine potential reasons for it by examining individual study and subgroup characteristics.

We expect the following characteristics to introduce clinical heterogeneity:

  • age of participants and age at which oxandrolone treatment was started;
  • dose of oxandrolone;
  • duration of oxandrolone therapy.

 

Assessment of reporting biases

If we include 10 studies or more for a given outcome, we will use funnel plots to assess small study effects. Due to several possible explanations for funnel plot asymmetry we will interpret results carefully (Sterne 2011).

 

Data synthesis

Unless there is good evidence for homogeneous effects across studies we will primarily summarise low risk of bias data by means of a random-effects model (Wood 2008). We will interpret random-effects meta-analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (Higgins 2009). A prediction interval specifies a predicted range for the true treatment effect in an individual study (Riley 2011). In addition, we will perform statistical analyses according to the statistical guidelines referenced in the latest version of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

 

Subgroup analysis and investigation of heterogeneity

We will carry out the following subgroup analyses and plan to investigate interaction.

  • Participants who reached their final adult height at the end of the study versus those who did not reach their final height.
  • Participants who received intervention or comparator for three years versus less than three years.
  • Participants who received low-dose oxandrolone (0.03 mg/kg/d) versus those who received high-dose oxandrolone (0.06 mg/kg/d).

 

Sensitivity analysis

We will perform sensitivity analyses in order to explore the influence of the following factors on effect sizes.

  • Restricting the analysis to published studies.
  • Restricting the analysis by taking into account risk of bias, as specified above.
  • Restricting the analysis to very long or large studies to establish how much they dominate the results.
  • Restricting the analysis to studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.

We will also test the robustness of the results by repeating the analysis using different measures of effect size (RR, OR etc.) and different statistical models (fixed-effect and random-effects models).

 

Acknowledgements

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

The authors (SM, YA, KA) would like to acknowledge the following physicians for their support during the planning and development of this systematic review:

Dr Lubna Al-Ansary, Holder of Shaikh Bahmdan's Chair of Evidence Based Medicine and Translation of Knowledge, King Saud University;

Dr Abdulrahman MH Al Nemri, Chief of Pediatrics Department, College of Medicine, King Saud University;

Prof Nasir AM Al-Jurayyan, Head of Pediatric Endocrinology Unit, King Saud University;

Dr Amir Babiker, Consultant Pediatric Endocrinologist, King Saud University.

 

Appendices

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support
 

Appendix 1. Search strategies


Search terms and databases

Unless otherwise stated, search terms are free text terms.

Abbreviations:

'$': stands for any character; '?': substitutes one or no character; adj: adjacent (i.e. number of words within range of search term); exp: exploded MeSH; MeSH: medical subject heading (MEDLINE medical index term); pt: publication type; sh: MeSH; tw: text word.

The Cochrane Library

#1 MeSH descriptor Turner syndrome explode all trees
#2  ( (Turner in All Text near/6 syndrom* in All Text) or (Ullrich-Turner in All Text near/6 syndrom* in All Text) or (bonnevie-ullrich in All Text near/6 syndrom* in All Text) )
#3  (#1 or #2)
#4  MeSH descriptor Oxandrolone explode all trees
#5  (oxandrolone in All Text or oxandrin in All Text or anavar in All Text)
#6  (#4 or #5)
#7  (#3 and #6)

MEDLINE

1   exp Turner Syndrome/
2   ((turner or ullrich-turner or bonnevie-ullrich) adj6 syndrom*).tw,ot.
3   1 or 2
4   exp Oxandrolone/
5   (oxandrolone or oxandrin or anavar).tw,ot.
6   4 or 5
7   3 and 6
8   randomized controlled trial.pt.
9   controlled clinical trial.pt.
10  randomi?ed.ab.
11  placebo.ab.
12  drug therapy.fs.
13  randomly.ab.
14  trial.ab.
15  groups.ab.
16  or/8-15
17  Meta-analysis.pt.
18  exp Technology Assessment, Biomedical/
19  exp Meta-analysis/
20  exp Meta-analysis as topic/
21  hta.tw,ot.
22  (health technology adj6 assessment$).tw,ot.
23  (meta analy$ or metaanaly$ or meta?analy$).tw,ot.
24  (search* adj10 (medical databas*or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or biosis or current content*)).tw,ot.
25  (systematic adj3 review*).tw,ot.
26  or/17-25
27  16 or 26
28  (comment or editorial or historical-article).pt.
29  27 not 28
30  7 and 29
31  limit 30 to humans

EMBASE

1   exp Turner Syndrome/
2   ((turner or ullrich-turner or bonnevie-ullrich) adj6 syndrom*).tw,ot.
3   1 or 2
4   exp Oxandrolone/
5  (oxandrolone or oxandrin or anavar).tw,ot.
6   4 or 5
7  3 and 6
8   exp Randomized Controlled Trial/
9   exp Controlled Clinical Trial/
10  exp Clinical Trial/
11  exp Comparative Study/
12  exp Drug comparison/
13  exp Randomization/
14  exp Crossover procedure/
15  exp Double blind procedure/
16  exp Single blind procedure/
17  exp Placebo/
18  exp Prospective Study/
19  ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).ab,ti.
20  (random$ adj6 (allocat$ or assign$ or basis or order$)).ab,ti.
21  ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).ab,ti.
22  (cross over or crossover).ab,ti.
23  or/8-22
24  exp meta analysis/
25  (metaanaly$ or meta analy$ or meta?analy$).ab,ti,ot.
26  (search$ adj10 (medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or biosis or current content$ or systematic$)).ab,ti,ot.
27  exp Literature/
28  exp Biomedical Technology Assessment/
29  hta.tw,ot.
30  (health technology adj6 assessment$).tw,ot.
31  or/24-30
32  23 or 31
33  (comment or editorial or historical-article).pt.
34  32 not 33
35  7 and 34
36  limit 35 to human

'My NCBI' alert service

("turner syndrome"[MeSH Terms] OR ("turner"[All Fields] AND "syndrome"[All Fields]) OR "turner syndrome"[All Fields]) AND ("oxandrolone"[MeSH Terms] OR "oxandrolone"[All Fields])

Manufacturers' websites, FDA and EMA websites

oxandrolone



 

Appendix 2. Description of interventions


CharacteristicIntervention(s) [route, frequency, total dose/day]Adequatea intervention

[Yes / No]
Comparator(s) [route, frequency, total dose/day]Adequatea comparator

[Yes / No]

Study 1Intervention 1Comparator 1

Intervention 2Comparator 2

Footnotes

"-" denotes not reported

aThe term 'adequate' refers to sufficient use of the intervention/comparator with regard to dose, dose escalation, dosing scheme, provision for contraindications and other features necessary to establish a fair contrast between intervention and comparator

N: no; Y: yes



 

Appendix 3. Baseline characteristics (I)


CharacteristicIntervention(s) and comparator(s)Duration of intervention (duration of follow-up)Participating populationStudy period [year to year]CountrySettingEthnic groups [%]Duration of disease [mean/range years (SD), or as reported]

Study 1Intervention 1

Intervention 2

Comparator 1

Comparator 2

all:





Footnotes

"-" denotes not reported

SD: standard deviation



 

Appendix 4. Baseline characteristics (II)


CharacteristicIntervention(s) and comparator(s)Age [mean/range years (SD), or as reported]Age when therapy was started [years]Co-medications / Co-interventionsCo-morbidities

Study 1Intervention 1

Intervention 2

Comparator 1

Comparator 2

all:

Footnotes

"-" denotes not reported

SD: standard deviation



 

Appendix 5. Matrix of study endpoints (publications)


CharacteristicEndpoint reported in publicationEndpoint not reported in publicationEndpoint not
measured
Time of measurementa

ExampleReview's primary outcomes

Final adult height / growth velocityx6, 12 mo

Health-related quality of lifexN/A

Adverse effectsx12 mo

Review's secondary outcomes

All-cause mortality

Bone maturationx12 mo

Effects on cognitionx0, 6, 12 mo

Effects on psychological statusxN/A

Effects on speechx12, 24 mo

Socioeconomic costsxN/A

Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b

Patient satisfaction (S)

Subgroups reported in publication

Children versus adolescents


Footnotes

aUnderlined data denote times of measurement for primary and secondary review outcomes, if measured and reported in the results section of the publication (other times represent planned but not reported points in time).

b(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes which were not specified as 'primary' or 'secondary' outcomes in the publication.

mo: months; N/A: not acknowledged



 

Appendix 6. Matrix of study endpoints (trial documents)


Characteristic / Study ID (trial identifier)EndpointaReview's primary outcomeReview's secondary outcomeTime of measurementSource (FDA document / EMA document / manufacturer's website / design paper / trial protocol document)

E x a m p l eFinal adult height / growth velocitya (P)bx12 mo

Health-related quality of life (P)x3, 6, 12 mo

Costs (O)x12 mo

Adverse events (S)x6, 12 mo

Footnotes

"-" denotes not reported

a(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes which were not specified as 'primary' or 'secondary' outcomes in the report.

mo: months; N/A: not acknowledged



 

Appendix 7. Examination of outcome reporting bias


CharacteristicClear that outcome was measured and analyseda [trial report states that outcome was analysed but only reports that result was not significant]Clear that outcome was measured and analysedb [trial report states that outcome was analysed but no results reported]Clear that outcome was measuredc [clear that outcome was measured but not necessarily analysed (judgement says likely to have been analysed but not reported because of non-significant results)]Unclear whether the outcome was measuredd [not mentioned but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results]

Study 1

Footnotes

'High risk of bias' categories for outcome reporting bias according to the Outcome Reporting Bias In Trials (ORBIT) study classification system for missing or incomplete outcome reporting in reports of randomised trials (Kirkham 2010).

aClassification 'A' (table 2, Kirkham 2010)

bClassification 'D' (table 2, Kirkham 2010)

cClassification 'E' (table 2, Kirkham 2010)

dClassification 'G' (table 2, Kirkham 2010)



 

Appendix 8. Definition of endpoint measurement


Characteristic

Study ID
Final adult heightIncrease in height velocityHealth-related quality of lifeBone maturationEffects on cognitionEffects on psychological statusEffects on speechSocioeconomic costsSevere / serious
adverse events

Study 1

Footnotes

ND: not defined



 

Appendix 9. Adverse events (I)


CharacteristicIntervention(s) and comparator(s)Randomised / Safety [N]Deaths [N]Deaths [%]All adverse events [N]All adverse events [%]Severe/serious adverse events [N]Severe/serious adverse events [%]

Study 1Intervention 1

Intervention 2

Comparator 1

Comparator 2

all:

Footnotes

"-" denotes not reported



 

Appendix 10. Adverse events (II)


CharacteristicIntervention(s) and comparator(s)Randomised / Safety [N]Left study due to adverse events [N]Left study due to adverse events [%]Hospitalisation [N]Hospitalisation [%]Out-patient treatment [N]Out-patient treatment [%]

Study 1Intervention 1

Intervention 2

Comparator 1

Comparator 2

all:

Footnotes

"-" denotes not reported



 

Appendix 11. Adverse events (III)


CharacteristicIntervention(s) and comparator(s)Randomised / Safety [N]Specific adverse events [description]Specific adverse events [N]Specific adverse events [%]

Study 1Intervention 1

Intervention 2

Comparator 1

Comparator 2

all:

Footnotes

"-" denotes not reported



 

Appendix 12. Survey of authors providing information on trials


CharacteristicStudy author contactedStudy author repliedStudy author asked for additional informationStudy author provided data

Study 1Y

Footnotes

N: no; Y: yes



 

Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Sarar Mohamed (SM): protocol draft, search strategy development, acquirement of trial copies, trial selection, data extraction, data analysis, data interpretation, review draft and review update.

Yaser Adi (YA): protocol draft, search strategy development, acquirement of trial copies, trial selection, data extraction, data analysis, data interpretation, review draft and review update.

Khalid AlFaleh (KA): protocol draft, search strategy development, acquirement of trial copies, trial selection, data extraction, data analysis, data interpretation, review draft and review update.

 

Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

None known

 

Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support
 

Internal sources

  • College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Saudi Arabia.
    Provide access to journals and references, computer, and secretarial assistance

 

External sources

  • Metabolic and Endocrine Group, Cochrane, Germany.
    Editing and reviewing protocol and helping with search strategy

References

Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Acknowledgements
  7. Appendices
  8. Contributions of authors
  9. Declarations of interest
  10. Sources of support
  11. Additional references
Andersson-Wallgren 2008
Bareille 1997
  • Bareille P, Massarano AA, Stanhope R. Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. European Journal of Pediatrics 1997;156:358-62.
Baxter 2007
Bell 2010
  • Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. Journal of Clinical Endocrinology and Metabolism 2010;95:167-77.
Bondy 2007
Canadian Growth Hormone Advisory Committee 2005
  • Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome:results of the Canadian randomised controlled trial. Journal of Clinical Endocrinology and Metabolism 2005;90:3360-6.
Carel 2005
  • Carel JC, Ecosse E, Sigeac IB, Cabrol S, Tauber M, Leger J, et al. Quality of life determinants in young women with Turner’s syndrome after growth hormone treatment: Results of the StaTur population-based cohort study. Journal of Clinical Endocrinology and Metabolism 2005;90:1992-7.
Carel 2006
  • Carel JC, Elie C, Ecosse E, Tauber M, Leger J, Cabrol S, et al. Self-esteem and social adjustment in young women with Turner syndrome - influence of pubertal management and sexuality: population-based cohort study. Journal of Clinical Endocrinology and Metabolism 2006;91:2972-9.
Carolyn 2007
  • Bondy CA. Clinical Practice Guidelines: Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. Journal of Clinical Endocrinology and Metabolism 2007;92:10–25.
Conway 2012
  • Conway C, Hammen C, Brennan P. A comparison of latent class, latent trait, and factor mixture models of DSM-IV borderline personality disorder criteria in a community setting: Implications for DSM-5. Journal of Personality Disorders 2012;26(5):793-803.
Davenport 1999
Davenport 2007
  • Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomised, controlled, multicenter trial. Journal of Clinical Endocrinology and Metabolism 2007;92:3406-16.
Fechner 2007
  •  Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. Journal of Clinical Endocrinology and Metabolism 2007;92:3406–16.
Garg 2011
  • Garg A, Garg S, She RW. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation. Burns 2011;37(7):1150-3.
Gault 2011
  • Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ 2011;342:doi: 10.1136/bmj.d1980 accessed 26 November 2012.
Gravholt 1996
  • Gravholt CH, Juul S, Naeraa RW, Hansen J. Prenatal and postnatal prevalence of Turner’s syndrome: a registry study. BMJ 1996;312:16-21.
Gravholt 2002
  • Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO, et al. Short term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity. A randomised double-blind, placebo-controlled cross-over study. Pediatrics 2002;110:889–96.
Haeusler 1996
  • Haeusler G, Schmitt K, Blümel P, Plöchl E, Waldhör T, Frisch H. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. Journal of Clinical Endocrinology and Metabolism 1996;81:536-41.
Hart 2001
Higgins 2002
Higgins 2003
Higgins 2009
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org accessed 26 November 2012.
Higgins 2011a
  • Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
Hróbjartsson 2013
  • Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201-11.
Job 1991
Joss 1984
Kirkham 2010
  • Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365 accessed 26 November 2012. [DOI: 10.1136/bmj.c365]
Liberati 2009
Mann 1999
Mazzanti 1998
  • Mazzanti L, Cacciari E. Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome. Journal of Pediatrics 1998;133(5):688-92.
Menke 2010
  • Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2010;95:1151-60.
Menke 2011
  • Menke LA, Sas TC, Stijnen T, Zandwijken GR, de Muinck Keizer-Schrama SM, Otten BJ, et al. Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. Hormone Research in Paediatrics 2011;75:115-22.
Naeraa 1990
Nielsen 1991
Nilsson 1996
  • Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenäs L, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. Journal of Clinical Endocrinology and Metabolism 1996;81:635-40.
Pinsker 2012
Ranke 2007
  • Ranke MB, Lindberg A, Ferrandez Longa s A, Darendeliler F. Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatric Research 2007;61:105-10.
Reh CS 2010
  •  Reh CS,  Geffner ME. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clinical Pharmacology: Advances and Applications 2010;2:111-22.
Riley 2011
  • Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
Rosenfeld 1992
  • Rosenfeld RG, Frane J, Attie KM, Brasel JA, Burstein S, Cara JF, et al. Six-year results of a randomised, prospective trial of human growth hormone and oxandrolone in Turner syndrome. Journal of Pediatrics 1992;121:49-55.
Ross 2006
Saenger 1999
Sheffield-Moore 1999
  • Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. Journal of Clinical Endocrinology and Metabolism 1999;84:2705-11.
Stahnke 2002
  • Stahnke N, Keller E, Landy H. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. Journal of Pediatric Endocrinology and Metabolism 2002;15:129-38.
Stephure 2005
  • Stephure DK. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomised controlled trial. Journal of Clinical Endocrinology and Metabolism 2005;90:3360-6.
Sterne 2011
  • Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
Stochholm 2006
  • Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2006;91:3897-902.
Taback 2011
  • Taback SP, Vlie GV. Health-related quality of life of young adults with Turner syndrome following a long-term randomised controlled trial of recombinant human growth hormone. BMC Pediatrics 2011;11:49. doi:10.1186/1471-2431-11-49.
Takeda 2010
  • Takeda A, Cooper K, Bird A, Baxter L, Frampton GK,  Gospodarevskaya E, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technology Assessment 2010;14(42):1-209. DOI: 10.3310/hta14420.
Tanaka 1999
Tracy 2011
  • Hadnott TN, Gould HN, Gharib AM, Bondy CA. Outcomes of spontaneous and assisted pregnancies in Turner syndrome: The NIH experience. Fertility and Sterility 2011;95(7):2251-6.
Turner 1938
  • Turner H. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938;23:566-74.
Ullrich 1930
  • Ullrich O. About typical combination of multiple images Abartungen [Über typische Kombinationsbilder multipler Abartungen]. Kinderheilkunde 1930;49:271-6.
Van Pareren 2003
  • Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC. Final height in girls withTurner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. Journal of Clinical Endocrinology and Metabolism 2003;88:1119-25.
Wechsler 1991
  • Wechsler D. Wechsler intelligence scale for children. third edition. San Antonio: The Psychological Corporation, 1991.
Wilson 1998
  • Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. Journal of Pediatrics 1988;112:210-7.
Wilton 1999
  • Ranke MB, Wilton P, editors. Progress in Growth Hormone Therapy in KIGS–10 year experience. Leipzig, Germany: Johann Ambrosius Barth Verlag, 1999.
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
Zeger 2011
  • Zeger MP, Shah K, Kowal K, Cutler GB Jr, Kushner H, Ross JL. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. Hormone Research in Paediatrics 2011;75:38-46.